|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
|
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/09/21 Mannkind Corp. 10-Q 9/30/21 96:14M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.53M
2: EX-10.1 Material Contract HTML 190K
3: EX-10.2 Material Contract HTML 37K
4: EX-10.3 Material Contract HTML 234K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 34K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 34K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 30K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 30K
15: R1 Document and Entity Information HTML 81K
16: R2 Condensed Consolidated Balance Sheets HTML 143K
17: R3 Condensed Consolidated Balance Sheets HTML 45K
(Parenthetical)
18: R4 Condensed Consolidated Statements of Operations HTML 107K
19: R5 Condensed Consolidated Statements of Comprehensive HTML 48K
Loss
20: R6 Condensed Consolidated Statements of Stockholders' HTML 193K
Deficit
21: R7 Condensed Consolidated Statements of Cash Flows HTML 181K
22: R8 Description of Business and Significant Accounting HTML 114K
Policies
23: R9 Accounts Receivable HTML 68K
24: R10 Inventories HTML 47K
25: R11 Property and Equipment HTML 104K
26: R12 Accrued Expenses and Other Current Liabilities HTML 66K
27: R13 Borrowings HTML 198K
28: R14 Collaboration, Licensing and Other Arrangements HTML 218K
29: R15 Fair Value of Financial Instruments HTML 108K
30: R16 Common and Preferred Stock HTML 38K
31: R17 Earnings Per Common Share ("Eps") HTML 102K
32: R18 Stock-Based Compensation Expense HTML 110K
33: R19 Commitments and Contingencies HTML 122K
34: R20 Income Taxes HTML 32K
35: R21 Subsequent Event HTML 32K
36: R22 Description of Business and Significant Accounting HTML 173K
Policies (Policies)
37: R23 Description of Business and Significant Accounting HTML 49K
Policies (Tables)
38: R24 Accounts Receivable (Tables) HTML 66K
39: R25 Inventories (Tables) HTML 46K
40: R26 Property and Equipment (Tables) HTML 104K
41: R27 Accrued Expenses and Other Current Liabilities HTML 65K
(Tables)
42: R28 Borrowings (Tables) HTML 159K
43: R29 Collaboration, Licensing and Other Arrangements HTML 202K
(Tables)
44: R30 Fair Value of Financial Instruments (Tables) HTML 103K
45: R31 Earnings Per Common Share ("Eps") (Tables) HTML 103K
46: R32 Stock-Based Compensation Expense (Tables) HTML 110K
47: R33 Commitments and Contingencies (Tables) HTML 117K
48: R34 Description of Business and Significant Accounting HTML 174K
Policies - Additional Information (Detail)
49: R35 Description of Business and Significant Accounting HTML 32K
Policies - Additional Information (Detail 1)
50: R36 Schedule of Reconciliation of Cash, Cash HTML 36K
Equivalents, and Restricted Cash (Detail)
51: R37 Schedule of Accounts Receivable, Net (Detail) HTML 43K
52: R38 Accounts Receivable - Additional Information HTML 44K
(Detail)
53: R39 Inventories - Components of Inventory (Detail) HTML 37K
54: R40 Inventories - Additional Information (Detail) HTML 33K
55: R41 Property and Equipment, Net (Detail) HTML 64K
56: R42 Property and Equipment, Net (Parenthetical) HTML 30K
(Detail)
57: R43 Depreciation Expense Related to Property and HTML 29K
Equipment (Detail)
58: R44 Property and Equipment - Additional Information HTML 35K
(Detail)
59: R45 Accrued Expenses and Other Current Liabilities HTML 49K
(Detail)
60: R46 Borrowings - Summary of Carrying Amount of HTML 50K
Principal Borrowings (Detail)
61: R47 Borrowings - Summary of Carrying Amount of HTML 35K
Principal Borrowings (Parenthetical) (Detail)
62: R48 Borrowings - Schedule of Line of Credit Facility HTML 68K
Debt and Key Terms (Detail)
63: R49 Borrowings - Schedule of Line of Credit Facility HTML 72K
Debt and Key Terms (Parenthetical) (Detail)
64: R50 Borrowings - Schedule of Maturities of Our HTML 46K
Borrowings (Detail)
65: R51 Borrowings - Senior Convertible Notes - Additional HTML 85K
Information (Detail)
66: R52 Borrowings - MidCap Credit Facility - Additional HTML 145K
Information (Detail)
67: R53 Borrowings - Mann Group Promissory Notes - HTML 91K
Additional Information (Detail)
68: R54 Borrowings - PPP Loan - Additional Information HTML 42K
(Detail)
69: R55 Borrowings - 2024 Convertible Notes - Additional HTML 50K
Information (Detail)
70: R56 Borrowings - Schedule of Amortization of Debt HTML 32K
Premium and Accretion of Debt Discount and Debt
Issuance Cost (Detail)
71: R57 Borrowings - Milestone Rights - Additional HTML 32K
Information (Detail)
72: R58 Schedule of Revenue from Collaborations and HTML 54K
Services (Detail)
73: R59 Collaboration, Licensing and Other Arrangements - HTML 135K
Additional Information (Detail)
74: R60 Collaboration, Licensing and Other Arrangements - HTML 61K
Revenue Allocation (Detail)
75: R61 Collaboration, Licensing and Other Arrangements - HTML 52K
Schedule of Revised Anticipated Cash Flows from
Transactions Allocated Performance Obligations
(Detail)
76: R62 Collaboration, Licensing and Other Arrangements - HTML 41K
Additional Information (Detail 1)
77: R63 Fair Value of Financial Instruments - Additional HTML 40K
Information (Detail)
78: R64 Fair Value of Financial Instruments - Fair Value HTML 62K
of Financial Instruments (Detail)
79: R65 Fair Value of Financial Instruments - Fair Value HTML 70K
of Financial Instruments (Parenthetical) (Detail)
80: R66 Common and Preferred Stock - Additional HTML 98K
Information (Detail)
81: R67 Earnings Per Common Share ("EPS") - Components of HTML 44K
Basic and Diluted EPS Computations (Detail)
82: R68 Earnings Per Common Share ("EPS") - Potential HTML 51K
Dilutive Securities Outstanding that are
Considered Antidilutive (Detail)
83: R69 Stock-Based Compensation - Schedule of Employee HTML 38K
Awards and Non-employee Director Award Plan
Activity (Detail)
84: R70 Stock-Based Compensation - Schedule of Employee HTML 63K
Awards and Non-employee Director Award Plan
Activity (Parenthetical) (Detail)
85: R71 Stock-Based Compensation Expense - Additional HTML 63K
Information (Detail)
86: R72 Stock-Based Compensation Expense - Stock Based HTML 35K
Compensation Expense Recognized in Condensed
Consolidated Statements of Operations (Detail)
87: R73 Commitments and Contingencies - Additional HTML 84K
Information (Detail)
88: R74 Commitments and Contingencies - Remaining Purchase HTML 41K
Requirements (Detail)
89: R75 Commitments and Contingencies - Summary of Lease HTML 34K
Information (Detail)
90: R76 Commitments and Contingencies - Schedule of Lease HTML 31K
Term and Discount Rate (Detail)
91: R77 Commitments and Contingencies - Schedule of Future HTML 41K
Minimum Office And Vehicle Lease Payments (Detail)
92: R78 Subsequent Event - Additional Information (Detail) HTML 58K
94: XML IDEA XML File -- Filing Summary XML 177K
14: XML XBRL Instance -- mnkd-10q_20210930_htm XML 3.36M
93: EXCEL IDEA Workbook of Financial Reports XLSX 146K
10: EX-101.CAL XBRL Calculations -- mnkd-20210930_cal XML 216K
11: EX-101.DEF XBRL Definitions -- mnkd-20210930_def XML 1.14M
12: EX-101.LAB XBRL Labels -- mnkd-20210930_lab XML 1.67M
13: EX-101.PRE XBRL Presentations -- mnkd-20210930_pre XML 1.52M
9: EX-101.SCH XBRL Schema -- mnkd-20210930 XSD 283K
95: JSON XBRL Instance as JSON Data -- MetaLinks 475± 750K
96: ZIP XBRL Zipped Folder -- 0001564590-21-055727-xbrl Zip 416K
Exhibit 10.2
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL.
FIRST AMENDMENT
TO
COMMERCIAL SUPPLY AGREEMENT
This amendment is effective the last date signed by a party, between MannKind Corporation, a Delaware corporation (“MannKind”), having a principal place of business at 30930 Russell Ranch Road, Suite 301, Westlake Village, California 91362, and United Therapeutics Corporation, a Delaware corporation (“United Therapeutics”), having a principal place of business at 1040 Spring Street, Silver Spring, Maryland 20910.
WHEREAS, the parties to this amendment entered into a Commercial Supply Agreement effective as of August 12, 2021 (as amended from time to time, the “Agreement”), and the parties now wish to amend the Agreement as set forth below.
NOW, THEREFORE, in consideration of the terms and conditions specified herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:
|
|
1. |
AMENDMENT. |
|
|
a. |
The second sentence of Section 1.11 (Cost of Goods) is hereby amended and replaced with the following sentence: |
In addition, COGs will include an annual facility utilization expense (or rent) of $[***] (increasing to $[***] on December 1, 2021 and thereafter) per square foot for the portion of the Facility allocated to activities under this Agreement; provided, however, that such facility utilization expense shall not be subject to the Margin.
|
|
b. |
Section 8.1 (Term) of the Agreement is hereby amended and restated in its entirety as follows: |
|
|
8.1 |
Term. The term of this Agreement (the “Term”) shall begin on the Effective Date and continue until December 31, 2031. This Agreement shall thereafter be automatically renewed for two-year renewal terms (each such period a “Renewal Term”) unless: (a) United Therapeutics provides notice to MannKind at least 24 months in advance of such renewal that United Therapeutics does not wish to renew this Agreement; or (b) MannKind provides notice to United Therapeutics at least 48 months in advance of such renewal that MannKind does not wish to renew this Agreement |
Page 1 of 3
|
|
2. |
GENERAL. All terms of the Agreement that are not specifically modified by this amendment remain in full force and effect. The parties may execute this amendment in counterparts, each of which is deemed an original for all purposes, and which together will constitute the same instrument. The parties may execute this amendment by electronic means (electronic signature through generally recognized e-signature vendors), by scanned pdfs of wet-ink signed documents, or by return of originals. |
***
Signature page follows
Page 2 of 3
IN WITNESS WHEREOF, the parties have caused this amendment to be signed by their duly authorized representatives as of the date indicated below.
|
United Therapeutics Corporation
By:/s/ Patrick Poisson Name:Patrick Poisson Title:EVP, Technical Operations Date:October 15, 2021 |
MannKind Corporation
By:/s/ Joe Kocinsky Name:Joe Kocinsky Title:Chief Technology Officer Date:October 16, 2021 |
|
|
|
Page 3 of 3
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 12/31/31 | ||||
| 12/1/21 | ||||
| Filed on: | 11/9/21 | 8-K | ||
| 10/16/21 | 8-K | |||
| 10/15/21 | ||||
| For Period end: | 9/30/21 | |||
| 8/12/21 | 8-K/A | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/27/24 Mannkind Corp. 10-K 12/31/23 123:18M Donnelley … Solutions/FA 2/23/23 Mannkind Corp. 10-K 12/31/22 135:24M ActiveDisclosure/FA 2/24/22 Mannkind Corp. 10-K 12/31/21 108:17M ActiveDisclosure/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/05/21 Mannkind Corp. 8-K:1,2,3,8 3/01/21 14:1M Donnelley … Solutions/FA 5/27/20 Mannkind Corp. 8-K:5,8,9 5/21/20 3:189K Donnelley … Solutions/FA 4/15/20 Mannkind Corp. 8-K:2,8,9 4/10/20 2:68K Donnelley … Solutions/FA 8/07/19 Mannkind Corp. 8-K:1,2,3,9 8/02/19 12:1.7M Donnelley … Solutions/FA 12/13/17 Mannkind Corp. 8-K:5,9 12/13/17 2:24K Donnelley … Solutions/FA 3/16/17 Mannkind Corp. 10-K 12/31/16 99:9M Donnelley … Solutions/FA 3/02/17 Mannkind Corp. 8-K:5,9 3/01/17 2:29K Donnelley … Solutions/FA 8/09/16 Mannkind Corp. 10-Q 6/30/16 65:3.7M Donnelley … Solutions/FA 7/01/13 Mannkind Corp. 8-K:1,2,3,9 7/01/13 6:650K Donnelley … Solutions/FA |